Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | METAP2 | P50579 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KDR | P35968 | 7/20 | 0.43 |
| ▸ | FLT1 | P17948 | 6/20 | 0.42 |
| ▸ | CIT | O14578 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | HLA-A | P04439 | 1/20 | 0.42 |
| ▸ | CSF1R | P07333 | 1/20 | 0.42 |
| ▸ | RET | P07949 | 1/20 | 0.42 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.42 |
| ▸ | KIT | P10721 | 1/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.42 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.42 |
| ▸ | FLT4 | P35916 | 1/20 | 0.42 |
| ▸ | FRK | P42685 | 1/20 | 0.42 |
| ▸ | CDK8 | P49336 | 1/20 | 0.42 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.42 |
| ▸ | STK3 | Q13188 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1346368 | 0.89 | LMNA (0.47) | MEN1KMT2AALDH1A1KDRFLT1 | |
| SCHEMBL1346264 | 0.84 | ALDH1A1 (0.39) | MEN1KMT2AMETAP2ALDH1A1KDR | |
| SCHEMBL1344762 | 0.81 | KDR (0.51) | MEN1KMT2AMETAP2ALDH1A1KDR | |
| SCHEMBL1346462 | 0.79 | KDR (0.44) | MEN1KMT2AALDH1A1KDRFLT1 | |
| SCHEMBL1346725 | 0.79 | KDR (0.46) | MEN1KMT2AMETAP2ALDH1A1KDR | |
| SCHEMBL1344767 | 0.74 | FLT1 (0.46) | MEN1KMT2AKDRFLT1CIT | |
| SCHEMBL23657806 | 0.74 | BLM (0.66) | MEN1KMT2AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL1346997 | 0.72 | MAPT (0.45) | MEN1KMT2AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL12134587 | 0.72 | GSK3A (0.38) | MEN1KMT2AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL1344882 | 0.71 | KMT2A (0.51) | MEN1KMT2AALDH1A1KDRFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063034-B2 | Oxadiazole derivatives and thiadiazole derivatives having neovascularization inhibitory activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-11-22 | — | — | US | claimed |
| US-20100016354-A1 | NOVEL OXADIAZOLE DERIVATIVES AND THIADIAZOLE DERIVATIVES HAVING NEOVASCULARIZATION INHIBITORY ACTIVITY | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | claimed |
| EP-2128156-A1 | NOVEL OXADIAZOLE DERIVATIVES AND THIADIAZOLE DERIVATIVES HAVING NEOVASCULARIZATION INHIBITING ACTIVITY | Santen Pharmaceutical Co., Ltd (JP) | 2009-12-02 | — | — | EP | claimed |
| US-8063034-B2 | Oxadiazole derivatives and thiadiazole derivatives having neovascularization inhibitory activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-11-22 | — | — | US | disclosed |
| US-8063034-B2 | Oxadiazole derivatives and thiadiazole derivatives having neovascularization inhibitory activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-11-22 | — | — | US | disclosed |
| US-8063034-B2 | Oxadiazole derivatives and thiadiazole derivatives having neovascularization inhibitory activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-11-22 | — | — | US | disclosed |
| US-20100016354-A1 | NOVEL OXADIAZOLE DERIVATIVES AND THIADIAZOLE DERIVATIVES HAVING NEOVASCULARIZATION INHIBITORY ACTIVITY | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| US-20100016354-A1 | NOVEL OXADIAZOLE DERIVATIVES AND THIADIAZOLE DERIVATIVES HAVING NEOVASCULARIZATION INHIBITORY ACTIVITY | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| US-20100016354-A1 | NOVEL OXADIAZOLE DERIVATIVES AND THIADIAZOLE DERIVATIVES HAVING NEOVASCULARIZATION INHIBITORY ACTIVITY | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-2128156-A1 | NOVEL OXADIAZOLE DERIVATIVES AND THIADIAZOLE DERIVATIVES HAVING NEOVASCULARIZATION INHIBITING ACTIVITY | Santen Pharmaceutical Co., Ltd (JP) | 2009-12-02 | — | — | EP | disclosed |
| EP-2128156-A1 | NOVEL OXADIAZOLE DERIVATIVES AND THIADIAZOLE DERIVATIVES HAVING NEOVASCULARIZATION INHIBITING ACTIVITY | Santen Pharmaceutical Co., Ltd (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016354-A1 | NOVEL OXADIAZOLE DERIVATIVES AND THIADIAZOLE DERIVATIVES HAVING NEOVASCULARIZATION INHIBITORY ACTIVITY | FLT4, VEGFA, FLT1 | MEN1 4661/4885KMT2A 4259/4885METAP2 4168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.